Application of serum thymidine kinase 1 of 26 055 cases in health screening for early detection of premalignant/early malignant tumors.
10.11817/j.issn.1672-7347.2014.10.007
- Author:
Xia CAO
1
;
Yaqin WANG
;
Pingting YANG
;
Hui ZHOU
;
Chang LIU
;
Zhiheng CHEN
Author Information
1. Health Management Center, Third Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor;
blood;
Breast;
pathology;
Cross-Sectional Studies;
Early Detection of Cancer;
Female;
Humans;
Hyperplasia;
Male;
Neoplasms;
diagnosis;
Precancerous Conditions;
diagnosis;
Prostate;
pathology;
Thymidine Kinase;
blood
- From:
Journal of Central South University(Medical Sciences)
2014;39(10):1029-1034
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To determine the application of serum thymidine kinase 1 (STK1) in general health screening for early detection of premalignant/early malignant tumors.
METHODS:A cross sectional study was carried out in 26 055 health screenings from 8 centers of Changsha in 2011. The concentration of STK1 was determined by a sensitive chemiluminescent dot blot ECL assay.
RESULTS:In the elevated STK1 group 60.35% showed diseases with a higher risk of premalignant/ early cancerous progression. The positive rate of elevated STK1 (>2.0 pmol/L) was 2.61%. There was a significantly higher rate with moderate/severe type of hyperplasia of breasts and prostate with elevated STK1 than people with normal STK1 values.
CONCLUSION:STK1 may be a reliable marker for risk assessment of premalignant/early malignant tumors.
